{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 39,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/17",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Inhibition of the key cytokines IL-2, IL-9 and IL-15 by EQ101 translates from preclinical models into humans",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48e90daa-8056-4cbd-a489-cea08a96b04f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.03,
        "y": 0.54
      },
      "kind": "list",
      "text": "IL-2 & IL-15 are important to CD8 and NK cell biology, IL-9 contributes to inflammation in the skin. Important to inhibit both IL-2 and IL-15 due to redundancy in signaling on cytotoxic CD8 T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51005f87-3823-4cb2-8c81-93681eecd121",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.27,
        "y": 0.54
      },
      "kind": "list",
      "text": "PEGylated peptide (based on the D-helix) selectively inhibiting IL-2, IL-9 & IL-15 signaling. Administered as a low volume intravenous push, with a sub-cutaneous formulation in development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ea71c4d-d7ce-4f8f-8807-08eab035cf7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.51,
        "y": 0.54
      },
      "kind": "list",
      "text": "As effective as ruxolitinib in inhibiting multiple lymphoproliferative or leukemic T-cell lines. More effective than ruxolitinib in mouse model of immune-mediated hair loss / alopecia areata",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a462a4e8-4116-4955-9e1f-110d69222489",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.75,
        "y": 0.54
      },
      "kind": "list",
      "text": "Significant clinical experience in >100 subjects, demonstrated favorable safety and tolerability. Positive proof-of-concept achieved in cutaneous T cell lymphoma patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff64ce61-4612-4d32-b099-d1227af26e87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Nata et al., J. Biol. Chem., 2015; 2) Massoud et al., PNAS, 2015; 3) Wang et al., Leukemia, 2018; 4) Azimi et al., AHRS, Orlando, Florida, 2018 5) Frohna et al., J. Clin. Pharm., 2019 6) Querfeld et al., Blood, 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76b3648d-68dc-473c-a5f9-275927e981aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: A First-in-Class Tri-Specific Cytokine Inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "267e00a5-c74c-4e22-b4e0-237b3250a8ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}